RISK OF RECURRENCE AMONG PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, EARLY BREAST CANCER RECEIVING ADJUVANT ENDOCRINE THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Ramirez, Oliva A. [1 ]
Law, E. H. [2 ]
Cueto, J. [2 ]
Salvo, E. M. [1 ]
Situ, A. [1 ]
Samjoo, I. A. [1 ]
机构：
[1] EVERSANA, Burlington, ON, Canada
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN43
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [41] Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis (vol 6, 100088, 2021)
    Hasson, S. Peleg
    Brezis, M. R.
    Shachar, E.
    Shachar, S. S.
    Wolf, I.
    Sonnenblick, A.
    ESMO OPEN, 2021, 6 (03)
  • [42] Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR-Positive Breast Cancer
    Wang, Wei
    Liu, Chenghao
    Zhou, Wenbin
    Xia, Tiansong
    Xie, Hui
    Wang, Shui
    SCIENTIFIC REPORTS, 2016, 6
  • [43] Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis
    Martins-Branco, Diogo
    Nader-Marta, Guilherme
    Molinelli, Chiara
    Ameye, Lieveke
    Paesmans, Marianne
    Ignatiadis, Michail
    Aftimos, Philippe
    Salgado, Roberto
    de Azambuja, Evandro
    EUROPEAN JOURNAL OF CANCER, 2023, 194
  • [44] Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive, HER2-negative early breast cancer.
    Calip, Gregory Sampang
    Hubbard, Colin
    Nabulsi, Nadia Azmi
    Asfaw, Alemseged Ayele
    Lee, Inyoung
    Zhou, Jifang
    Cueto, Jenilee
    Mitra, Debanjali
    Law, Ernest H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negative advanced breast cancer
    Song, Xifu
    Lu, Jingjing
    Wang, Liyan
    Kong, Feifei
    Yuan, Hangyu
    Chen, Cheng
    Shan, Haixia
    JOURNAL OF BUON, 2020, 25 (05): : 2228 - 2236
  • [46] Second-line Endocrine Therapy of Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis
    Wang, Tianzhuo
    Shen, Guoshuang
    Li, Jinming
    Huo, Xingfa
    Wang, Miaozhou
    Liu, Zhen
    Zhao, Fuxing
    Ren, Dengfeng
    Zhao, Jiuda
    CURRENT CANCER DRUG TARGETS, 2023, 23 (09) : 718 - 730
  • [47] Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
    Brandao, Mariana
    Maurer, Christian
    Ziegelmann, Patricia Klarmann
    Ponde, Noam F.
    Ferreira, Arlindo
    Martel, Samuel
    Piccart, Martine
    de Azambuja, Evandro
    Debiasi, Marcio
    Lambertini, Matteo
    ESMO OPEN, 2020, 5 (04)
  • [48] ECONOMIC ASSESSMENT OF RIBOCICLIB FOR THE TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER HR-POSITIVE, HER2-NEGATIVE
    Velasquez, M.
    Medina, Bustos L.
    Chacon, Zagarra C.
    Rojas, R.
    VALUE IN HEALTH, 2022, 25 (01) : S84 - S84
  • [49] Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer Reply
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Toi, Masakazu
    Martin, Miguel
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1507 - +
  • [50] Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review
    de Mello Morais Mata, Danilo Giffoni
    Carmona, Carlos Amir
    Eisen, Andrea
    Trudeau, Maureen
    CURRENT ONCOLOGY, 2022, 29 (07) : 4956 - 4969
12345